Targeting ASK1 by CS17919 alleviates kidney‐ and liver‐related diseases in murine models
Animal Models and Experimental Medicine · 2025-01 · 8 (1) · 102-113
DOI: 10.1002/ame2.12437 ↗Kurz gefasst
Fachartikel in der Zeitschrift Animal Models and Experimental Medicine, online erschienen am 14.06.2024. Verfasst von Guoqiang Liao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Chengdu Chipscreen Pharmaceutical Corp., Ltd., Chengdu, Sichuan, P.R. China. Hauptthemen laut MEDLINE: MAP Kinase Kinase Kinase 5, Renal Insufficiency, Chronic, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Apoptosis signal‐regulating kinase 1 (ASK1) is a MAP3K kinase in the MAPK signaling pathway activated by stressors and triggers downstream biological effects such as inflammation and apoptosis; therefore, inhibition of ASK1 kinase activity can protect cells from pathological injury. In this study, we designed and synthesized a novel selective ASK1 inhibitor, CS17919, and investigated its pharmacological effects in various animal models of metabolic injury.
Methods
First, we validated the ability of CS17919 to inhibit ASK1 in vitro and then tested the safety profile of CS17919 in cell lines compared with Selonsertib (GS‐4997), a phase III ASK1 inhibitor. We then conducted pharmacokinetic (PK) studies in mice. Finally, we tested the in vivo efficacy of CS17919 in murine models of chronic kidney disease (CKD) and non‐alcoholic steatohepatitis (NASH).
Results
Compared to GS‐4997, CS17919 demonstrated comparable inhibition of ASK1 in vitro, exhibited lower toxicity, and provided greater protection in palmitic acid‐treated LO2 cells. CS17919 also showed pronounced pharmacokinetic properties such as a high plasma concentration. In the unilateral ureteral obstruction model (UUO), CS17919 and GS‐4997 preserved kidney function and showed a non‐significant tendency to alleviate kidney fibrosis. In the diabetic kidney disease (DKD) model, CS17919 significantly improved serum creatinine and glomerular sclerosis. In the NASH model, the combination of CS17919 and a THRβ agonist (CS27109) was found to significantly improve liver inflammation and substantially reduced liver fibrosis.
Conclusions
CS17919 showed cell protective, anti‐inflammatory, and antifibrotic effects in vitro and in vivo, suggesting its therapeutic potential for metabolic‐related kidney and liver diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chengdu Chipscreen Pharmaceutical Corp., Ltd., Chengdu, Sichuan, P.R. China.
- Laboratory of Experimental Animal Disease Model, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan, P.R. China.
- Shenzhen Chipscreen Biosciences Co., Ltd., Shenzhen, Guangdong, P.R. China.
ORCID-Profile: Guoqiang Liao
Zitieren
APA
Liao, G., Yang, Q., Mao, X., Zhao, Y., Chen, B., Zhang, K., Zhang, Y., Zhang, P., Chen, Z., & Huang, S. (2025). Targeting ASK1 by CS17919 alleviates kidney‐ and liver‐related diseases in murine models. Animal Models and Experimental Medicine, 8(1), 102-113. https://doi.org/10.1002/ame2.12437
Vancouver
Liao G, Yang Q, Mao X, Zhao Y, Chen B, Zhang K, et al. Targeting ASK1 by CS17919 alleviates kidney‐ and liver‐related diseases in murine models. Animal Models and Experimental Medicine. 2025;8(1):102-113. doi:10.1002/ame2.12437
BibTeX
@article{Liao2025,
author = {Liao, Guoqiang and Yang, Qianjiao and Mao, Xuhua and Zhao, Yiru and Chen, Beizhong and Zhang, Kun and Zhang, Yu and Zhang, Ping and Chen, Zhengli and Huang, Shengjian},
title = {Targeting ASK1 by CS17919 alleviates kidney‐ and liver‐related diseases in murine models},
journal = {Animal Models and Experimental Medicine},
year = {2025},
volume = {8},
number = {1},
pages = {102--113},
doi = {10.1002/ame2.12437}
}
EUVIMED